Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2026)

Camp4 Therapeutics has reported Cash & Equivalents for 4 years, with the latest figure at $99.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 101.24% year-over-year to $99.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.2 million (up 101.24% YoY) and the FY2025 annual result came in at $109.5 million, up 71.02% from the prior year.
• Cash & Equivalents declined to $99.2 million in Q1 2026 per CAMP's latest filing, from $109.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $109.5 million in Q4 2025 and troughed at $2.5 million in Q3 2024.
• A 4-year average of $58.6 million and a median of $50.5 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 94.99% in 2024, then surged 2876.86% in 2025.
• Over 4 years, Cash & Equivalents stood at $38.4 million in 2023, then jumped by 66.86% to $64.0 million in 2024, then soared by 71.02% to $109.5 million in 2025, then decreased by 9.41% to $99.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $99.2 million, $109.5 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.